ArticleCurrent research in physiology2025
Protective effect of the Quercetin on experimental cuprizone-induced multiple sclerosis in male C57BL/6 mice.
Article in Current research in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential.Nutrients · 2026Review
- Review
- Synthesis and Evaluation of the Effects of Nanoparticles of Atorvastatin and Atorvastatin on Cuprizone-Induced Demyelination: Modulation of the Nrf2/NF-kB Signaling Pathway.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to determine protective effect of the Quercetin on experimental cuprizone-induced (CPZ) multiple sclerosis (MS) in Male C57BL/6 mice. Forty male C57BL/6 mice were allocated into 4 experimental groups. Control group received the standard diet. In group 2, mice received a diet containing 0.2 % (w/w) CPZ mixed with ground chow for a duration of 4 weeks (Zhu et al., 2021). In group 3, mice received Quercetin (150 mg/kg) orally every day for 4 weeks. In group 4, mice received a diet with 0.2 % CPZ and Quercetin (150 mg/kg) orally for 4 weeks. After incidence of the sign of the MS reflexive motor behavior and serum antioxidant levels were assessed. Based on the findings, administration of the CPZ significantly decreased ambulation score, number of crosses using OFT (open field test), stay on rotarod, hindlimb foot angle, front- and hindlimb suspension and grip strength (P < 0.05). Quercetin significantly increased ambulation score, number of cross using, stay on rotarod, hindlimb foot angle, front- and hindlimb suspension and grip strength (P < 0.05). Administration of the CPZ significantly increased serum malondialdehyde (MDA), tumor necrosis factor (TNF-α) and interleukin-1 beta (IL-1β) While decreased superoxide dismutase (SOD), glutathione peroxidase (GPX) and total antioxidant status (TAS) levels (P < 0.05). Quercetin significantly decreased serum MDA, TNF-α and IL-1β while increased SOD, GPX and TAS levels (P < 0.05). These results suggested, Quercetin has protective effect against CPZ-induced MS in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.